Navigation Links
Fatty acids involved in python heart growth could benefit diseased human heart
Date:10/27/2011

TUSCALOOSA, Ala. Identification of three fatty acids involved in the extreme growth of Burmese pythons' hearts following large meals could prove beneficial in treating diseased human hearts, according to research co-authored by a University of Alabama scientist and publishing in the Oct. 28 issue of Science.

Growth of the human heart can be beneficial when resulting from exercise a type of growth known as physiological cardiac hypertrophy but damaging when triggered by disease growth known as pathological hypertrophy. The new research shows a potential avenue by which to make the unhealthy heart growth more like the healthy version.

"We may later be able to turn the tables, in a sense, in the processes involved in pathological hypertrophy by administering a combination of fatty acids that occur in very high concentrations in the blood of digesting pythons," said Dr. Stephen Secor, associate professor of biological sciences at UA and one of the paper's co-authors. "This could trigger, perhaps, something more akin to the physiological form of hypertrophy."

The research, conducted in collaboration with multiple researchers at the University of Colorado working in the lab of Dr. Leslie Leinwand, identified three fatty acids, myristic acid, palmitic acid and palmitoleic acid, for their roles in the snakes' healthy heart growths following a meal.

Researchers took these fatty acids from feasting pythons and infused them into fasting pythons. Afterward, those fasting pythons underwent heart-rate growths similar to that of the feasting pythons. In a similar fashion, the researchers were able to induce comparable heart-rate growths in rats, indicating that the fatty acids have a similar effect on the mammalian heart.

The paper, whose lead author was Dr. Cecilia Riquelme of the University of Colorado, also showed that the pythons' heart growth was a result of the indi
'/>"/>

Contact: Chris Bryant
cbryant@ur.ua.edu
205-348-8323
University of Alabama in Tuscaloosa
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Liver parasite lacks key genes for fatty acid synthesis: Genome sequencing of Clonorchis sinensis
2. How fatty diets cause diabetes
3. Gene variant increases fatty liver risk and fibrosis progression
4. Scientists develop a fatty kryptonite to defeat multidrug-resistant Super bugs
5. Fish livers contain beneficial fatty acids
6. New data show non-alcoholic fatty liver disease will reach epidemic status in the US
7. New sleep cycle discovery explains why fatty diets during pregnancy make kids obese
8. Consuming polyunsaturated fatty acids may lower the incidence of gum disease
9. U of I study: Lack of omega-3 fatty acid linked to male infertility
10. U of I study: Lack of omega-6 fatty acid linked to severe dermatitis
11. How much omega-3 fatty acid do we need to prevent cardiovascular disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... technical, managerial and financial components of healthcare delivery to ... Disease) patient will be the topic of Stevens Institute ... October 31, 2007, from 3-5 p.m. in Room 122 ... Streets in Hoboken, NJ). , Roundtable participants will discuss ...
... a 46 percent increase in lifespan, raising the tantalizing ... are also taking an anti-aging medication. Results of the ... Lithgow, PhD, are currently published online in the Journal ... to treat mood affective disorders, including bipolar disease for ...
... daily commute may be taking more of a toll than ... of Southern California (USC) and the California Air Resources Board ... exposure to harmful air pollutants occurs while people are traveling ... spends about six percent (1.5 hours) of his or her ...
Cached Biology News:Stevens Health, Technology, and Society roundtable: Oct. 31 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Time spent in car drives up air pollution exposure 2
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 ... Lilly and Company (NYSE: LLY ) and ... positive results from a phase 2 study evaluating the ... on glycemic control in patients with type 2 diabetes. ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... a randomized pivotal trial of pixantrone for the treatment ... the  U.S. Food and Drug Administration,s (the "FDA") Division ... trial, referred to as the PIX-R or PIX 306 ...
... release is available in German . , From the ... to the strings and sound box of a guitar or violin, ... actual mechanical vibrations of these instruments create acoustic waves that we ... related to the decay of the vibration amplitude, that is, the ...
Cached Biology Technology:Exenatide Once Monthly Showed Positive Results in Phase 2 Study 2Exenatide Once Monthly Showed Positive Results in Phase 2 Study 3Exenatide Once Monthly Showed Positive Results in Phase 2 Study 4Exenatide Once Monthly Showed Positive Results in Phase 2 Study 5Exenatide Once Monthly Showed Positive Results in Phase 2 Study 6Exenatide Once Monthly Showed Positive Results in Phase 2 Study 7FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5How long does a tuning fork ring? 2
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Adhesion Molecule Antibodies...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: